Genmab — Juli 2014
-
en WACC på 15% vil jeg bruge når jeg tilbagediskonterer biotek ifht. den store risiko det jo har. Novod og Bowers ligger også på en 11-12% i WACC så vidt jeg husker
-
btw har jeg en rigtig god ide pt. ala bakka og protector. En fantastisk billig, valueaktie. Skal fortælle dig om den om en måneds tid. Skal lige se deres halvårsregnskab og have bekræftet om de leverer det jeg tror og håber
-
meget spændende!
-
Two new leukaemia drugs from Johnson & Johnson and Gilead Sciences have been recommended for approval by European regulators, paving the way for formal approval in a couple of months. http://finance.yahoo.com/news/europe-backs-leukaemia-drugs-j-112026984.html?.tsrc=applewf
-
MOR202 - Combinations with pomalidomide planned
MorphoSys and its collaboration partner Celgene Corporation have decided to expand the clinical development plan of MOR202 in multiple myeloma, introducing pomalidomide as a new combination partner. The MOR202 combination trials are now planned to be initiated earlier than originally anticipated. In addition, cohorts with a weekly dosing schedule, with and without dexamethasone, were added to the ongoing monotherapy trial of MOR202, which continue
-
as planned. The expanded design of the trial will be published on www.clinicaltrials.gov. As the now expanded Phase 1/2a trial will not be completed until 2015, the companies do not plan to publish any clinical data this year.
-
vildt at de først kommer med data i 2015 nok til ASCO
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind